Dr. Randy Vogenberg’s latest article explores the following key takeaways:
- Sustainable long-term financing models already exist, but broader adoption will require manufacturers, employers, and insurers to move beyond traditional approaches and embrace new risk pathways.
- Cell and gene therapies can deliver decades of clinical value but carry substantial upfront costs, creating affordability challenges that traditional annual insurance models were not designed to address.
- Employers, benefit experts, and industry stakeholders have recognized these financing challenges for decades and have explored alternative approaches to specialty drug coverage and risk management.
Read the full article at: https://www.hmpgloballearningnetwork.com/site/jcp/commentary/cell-and-gene-therapy-financing-moving-discussion-action